lamotrigine (Lamictal)

Subscribe to Selected New Research on lamotrigine

1490 relevant articles (297 outcomes, 361 trials/studies) found for this Drug

Description: blocks voltage-gated sodium and calcium channels and inhibits release of excitatory neurotransmitters such as glutamate; structure given in first source

Also Known As:

Lamictal; 3,5-diamino-6-(2,3-dichlorophenyl)-as-triazine; BW-430C; Crisomet; Desitin Brand of Lamotrigine; Faes Brand of Lamotrigine; Glaxo Wellcome Brand of Lamotrigine; GlaxoSmithKline Brand of Lamotrigine; Juste Brand of Lamotrigine; Labileno; Lamiktal

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 25

1-Ring Heterocyclic Compounds

Triazines: 28

lamotrigine: 1490

Experts

1.	Hammer, Anne E: 13 articles (03/2008 - 02/2003)
2.	Vuong, Alain: 10 articles (03/2008 - 02/2003)
3.	Calabrese, Joseph R: 9 articles (05/2008 - 01/2002)
4.	Bowden, Charles L: 8 articles (05/2008 - 10/2002)
5.	Ketter, Terence A: 7 articles (01/2008 - 02/2002)
6.	Messenheimer, John A: 6 articles (03/2008 - 08/2004)
7.	Luszczki, Jarogniew J: 5 articles (01/2008 - 11/2004)
8.	Brodie, Martin J: 5 articles (07/2007 - 09/2002)
9.	Post, R M: 5 articles (05/2007 - 04/2000)
10.	Marson, A G: 5 articles (01/2006 - 01/2000)

Related Diseases

1.	Seizures (Seizure) 03/01/1996 - "Efficacy measurements were comparable between the three treatment groups, although the higher lamotrigine dose was possibly most effective, with 60.4% completing seizure free compared with 51.3% (LTG 100) and 54.7% (CBZ 600). " 08/01/1990 - "Although there was no significant reduction in total seizure count during the lamotrigine treatment period compared to placebo, there appears to be a drug effect as there was a marked reduction in generalized tonic-clonic seizures in favour of lamotrigine in the last 4 weeks of the treatment period. " 08/01/2008 - "In this study-the first large prospective investigation of the long-term tolerability and efficacy of an antiepileptic drug in a patient population 2 years and younger-lamotrigine administered for up to approximately 72 weeks was well tolerated and associated with good seizure control." 01/01/2001 - "The overall Peto's Odds Ratio (OR) and 95% confidence intervals (CIs) across all studies for 50% or greater reduction in seizure frequency was 2.71 (1.87, 3.91) indicating that lamotrigine is significantly more effective than placebo in reducing seizure frequency. " 01/01/2000 - "The overall Peto's Odds Ratio (OR) and 95% confidence intervals (CIs) across all studies for 50% or greater reduction in seizure frequency was 2.71 (1.87, 3.91) indicating that lamotrigine is significantly more effective than placebo in reducing seizure frequency. " Order ALL the reference details at left...
2.	Bipolar Disorder (Mania) 10/01/2002 - "Lamotrigine has undergone a remarkable series of systematic studies since 1994 that now establish it as an efficacious, well-tolerated treatment in bipolar disorder. " 05/01/2006 - "RESULTS: The base-case model for patients with a recent manic episode indicated that lamotrigine is the most effective treatment for avoiding both acute depression episodes and all types of acute episodes (depression and mania). " 01/01/2004 - "Lamotrigine is the most widely studied and is effective in treating and preventing bipolar depression, and it is the only anticonvulsant approved by the U.S. " 05/01/2000 - "Lamotrigine has the most evidence in favor of its efficacy, with two double-blind studies in which it was more efficacious than placebo in the treatment of bipolar depression. " 04/01/2003 - "BACKGROUND: Lamotrigine has been shown to be an effective treatment for bipolar depression and rapid cycling in placebo-controlled clinical trials. " Order ALL the reference details at left...
3.	Epilepsy (Aura) 12/16/2001 - "CONCLUSIONS: The new anti-epileptic drugs have a major therapeutic advantage, not only in the management of epilepsy in different clinical situations, but also in the good results observed when using lamotrigine in patients of fertile age." 03/01/1998 - "PURPOSE: Lamotrigine (LTG) is a valuable addition to the medical management of epilepsy with wide spectrum of efficacy and good outcomes for quality of life. " 02/01/1998 - "OBJECTIVE: Lamotrigine as add-on treatment (500 mg per day) is effective in patients with refractory epilepsy, but its high cost requires a pharmacoeconomic analysis. " 01/01/2000 - "On the other hand, Lamotrigine seems to be more effective in patients with partial epileptic seizures with secondary generalization." 01/01/2008 - "The AED lamotrigine has been demonstrated to be effective in the treatment of depressive symptoms in patients with epilepsy. " Order ALL the reference details at left...
4.	Syndrome 06/01/1999 - " (4) In patients with the Lennox-Gastaut syndrome, the addiction of lamotrigine to an ongoing inadequately effective treatment proved more effective than a placebo in two methodologically sound trials. " 12/18/1997 - "METHODS: We conducted a double-blind, placebo-controlled trial of the antiepileptic drug lamotrigine in patients with the Lennox-Gastaut syndrome. " 08/31/2009 - "Sjögren's syndrome precipitated by lamotrigine treatment." 11/01/2006 - "Lamotrigine is well-tolerated and secondary aggravation of epileptic syndromes has rarely been reported. " 09/01/2005 - "For women who are pregnant or trying to conceive, lamotrigine was treatment of choice for both syndrome types. " Order ALL the reference details at left...
5.	Pain (Aches) 10/01/2007 - "Differences between lamotrigine and placebo were not statistically significant for secondary efficacy assessments, including mean changes from baseline in the Short-Form McGill Pain Questionnaire, the Neuropathic Pain Scale, rescue medication use, and the percentages of patients rated as much improved or very much improved at the end of treatment on the Clinician Global Impression of Change scale and the Patient Global Impression of Change scale. " 08/01/1998 - "Recent evidence suggests that lamotrigine, which is active at glutaminergic excitatory synapses, is very effective in producing pain relief. " 05/13/2003 - "CONCLUSIONS: Lamotrigine was well-tolerated and effective for HIV-associated neuropathic pain in patients receiving neurotoxic antiretroviral therapy. " 01/23/2001 - "CONCLUSIONS: Oral lamotrigine 200 mg daily is a well tolerated and moderately effective treatment for central poststroke pain. " 12/01/2000 - "CONCLUSION: A review of the literature suggests that lamotrigine may be effective in the management of neuropathic pain." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Valproic Acid (Valproate, Semisodium)
2.	Carbamazepine (Tegretol)
3.	topiramate (Topamax)
4.	gabapentin (Neurontin)
5.	Anticonvulsants (Antiepileptic Drugs)
6.	Vigabatrin
7.	felbamate (Felbatol)
8.	Lithium
9.	Phenytoin (Dilantin)
10.	oxcarbazepine (Trileptal)

Related Therapies and Procedures

1.	Vagus Nerve Stimulation
2.	Drug Therapy (Chemotherapy)
3.	Ketogenic Diet
4.	Hemispherectomy
5.	Relaxation Therapy

Best Treatments:
Research Summary Report
on Seizures

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 2227 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>